Microbot Medical

Company Overview

Snapshot

Founded in November 2010 by Harel Gadot, Microbot Medical operates with 11–50 employees. The company has raised $90.52 million across 15 funding rounds from 2 investors. In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System.

Business overview

Microbot Medical specializes in transformational robotic technologies, primarily focusing on the endovascular space. Its core product, the LIBERTY Robotic System, is the world’s first single-use endovascular robotic system designed to increase access to robotic technology and streamline endovascular procedures. The company serves the healthcare industry, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System. This regulatory approval is a significant validation of the company's technology and paves the way for commercialization, indicating strong forward momentum in bringing its robotic solutions to market and potentially revolutionizing endovascular procedures.

Company Intelligence Q&A

What was a significant recent regulatory achievement for Microbot Medical?

In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, a key milestone for commercialization.

What was the most recent funding event for Microbot Medical?

In October 2025, Microbot Medical announced the final closing of the exercise of outstanding preferred investment options, totaling up to $92.2 million in gross proceeds.

When did Microbot Medical commence the limited market release of its LIBERTY system?

In November 2025, Microbot Medical commenced the limited market release of its LIBERTY Endovascular Robotic System in the U.S.

Which institution was the first to adopt Microbot Medical's LIBERTY system?

In November 2025, Emory University Hospital was announced as the first hospital globally to adopt the new LIBERTY Endovascular Robotic System.

What was a recent intellectual property development for Microbot Medical?

In October 2025, Microbot Medical received its first patent in Japan, continuing to broaden its global intellectual property portfolio.